Page 141 - 2020_08-Haematologica-web

mTORi unlocks AML resistance to LSD1i
KDM1A inhibitor, for the treatment of acute
leukemia. Cancer Cell. 2018;33(3): 495-511.
15. Abdel-Aziz AK, Minucci S. Comparing apples with oranges: Studying LSD1 inhibitors in cellular assays. Pharmacol Res.
2019;146:104345.
16. Mohammad HP, Smitheman KN, Kamat
CD, et al. A DNA Hypomethylation signa- ture predicts antitumor activity of LSD1 inhibitors in SCLC. Cancer Cell. 2015; 28(1):57-69.
17. Ishikawa Y, Gamo K, Yabuki M, et al. A novel LSD1 inhibitor T-3775440 disrupts GFI1B-containing complex leading to trans- differentiation and impaired growth of AML cells. Mol Cancer Ther. 2017;16(2):273-284.
18. Hoshii T, Tadokoro Y, Naka K, et al. mTORC1 is essential for leukemia propaga- tion but not stem cell self-renewal. J Clin Invest. 2012;122(6):2114-2129.
19. Martelli AM, Evangelisti C, Chiarini F, McCubrey JA. The phosphatidylinositol 3- kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget. 2010;1(2): 89-103.
20. Zou Z, Chen J, Yang J, Bai X. Targeted inhi- bition of rictor/mTORC2 in cancer treat- ment: a new era after rapamycin. Curr Cancer Drug Targets. 2016;16(4):288-304.
21. Gao Y, Gao J, Li M, et al. Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia. J Hematol Oncol. 2016;9:1-14.
22. Burchert A, Wang Y, Cai D, et al. Compensatory PI3-kinase/Akt/mTor activa- tion regulates imatinib resistance develop- ment. Leukemia. 2005;19(10):1774-1782.
23. Elgendy M, Abdel-Aziz AK, Renne SL, et al. Dual modulation of MCL-1 and mTOR determines the response to sunitinib. J Clin Invest. 2017;127(1):153-168.
24. Malone CF, Emerson C, Ingraham R, et al. mTOR and HDAC inhibitors converge on the TXNIP/thioredoxin pathway to cause catastrophic oxidative stress and regression of RAS-driven tumors. Cancer Discov. 2017;7(12):1450-1463.
25. Fang J, Ying H, Mao T, et al. Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and sup- presses cell proliferation in human monocyt- ic leukemia cells. Oncotarget. 2017;8(49): 85085-85101.
26. Chow S, Minden MD, Hedley DW.
Constitutive phosphorylation of the S6 ribo- somal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients. Exp Hematol. 2006;34(9):1183- 1191.
tinib. Front Pharmacol. 2017;8:1-10.
36. PengX,ZhangD,LiZ,FuM,LiuH.mTOR inhibition sensitizes human hepatocellular carcinoma cells to resminostat. Biochem Biophys Res Commun. 2016;477(4):556-
27. Binda C, Valente S, Romanenghi M, et al. 562.
Biochemical, structural, and biological evalu- ation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. J Am Chem Soc. 2010;132(19): 6827-6833.
28. Kovacs K, Decatur C, Toro M, et al. 2- Deoxy-glucose downregulates endothelial AKT and ERK via interference with N-linked glycosylation, induction of endo- plasmic reticulum stress, and GSK3b sctiva- tion. Mol Cancer Ther. 2016;15(2): 264-275.
29. Inoki K, Ouyang H, Zhu T, et al. TSC2 inte- grates Wnt and energy signals via a coordi- nated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell. 2006; 126(5):955-968.
30. Machado-Neto JA, Favaro P, Lazarini M, Costa FF, Olalla Saad ST, Traina F. Knockdown of insulin receptor substrate 1 reduces proliferation and downregulates Akt/mTOR and MAPK pathways in K562 cells. Biochim Biophys Acta. 2011;1813 (8):1404-1411.
31. Fenerich BA, Machado-Neto JA, Alves AP, et al. The pharmacological IGF1R-IRS1/2 Inhibitor NT157 presents multiple antineo- plastic effects in myeloproliferative neo- plasms. Blood. 2017;130(Suppl 1):1253.
32. Del Rincón S V., Guo Q, Morelli C, Shiu HY, Surmacz E, Miller WH. Retinoic acid medi- ates degradation of IRS-1 by the ubiquitin- proteasome pathway, via a PKC-dependant mechanism. Oncogene. 2004;23(57):9269- 9279.
33. Ravikumar S, Perez-Liz G, Del Vale L, Soprano DR, Soprano KJ. Insulin receptor substrate-1 is an important mediator of ovarian cancer cell growth suppression by all-trans retinoic acid. Cancer Res. 2007; 67(19):9266-9275.
34. Goossens S, Peirs S, Loocke WV, et al. Oncogenic ZEB2 activation drives sensitivi- ty towards KDM1A inhibition in T-cell acute lymphoblastic leukemia. Blood. 2017; 129(8):981-990.
35. Abdel-Aziz AK, Abdel-Naim AB, Shouman S, Minucci S, Elgendy M. From resistance to sensitivity: insights and implications of biphasic modulation of autophagy by suni-
37. Feng S, Jin Y, Cui M ZJ. Lysine-specific demethylase 1 (LSD1) Inhibitor S2101 induces autophagy via the AKT/mTOR pathway in SKOV3 ovarian cancer cells. Med Sci Monit. 2016;22:4742-4748.
38. Poulain L, Sujobert P, Zylbersztejn F, et al. High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells. Leukemia. 2017;31(11):2326-2335.
39. Duteil D, Metzger E, Willmann D, et al. LSD1 promotes oxidative metabolism of white adipose tissue. Nat Commun. 2014;5:4093:1-31.
40. Hino S, Kohrogi K, Nakao M. Histone demethylase LSD1 controls the phenotypic plasticity of cancer cells. Cancer Sci. 2016;107(9):1187-1192.
41. Park H, Garrido-Laguna I, Naing A, et al. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget. 2016;7 (41):67521-67531.
42. Kerenyi MA, Shao Z, Hsu YJ, et al. Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation. Elife. 2013;2:e00633.
43. Abdulla A, Zhang Y, Hsu FN, et al. Regulation of lipogenic gene expression by lysine-specific histone demethylase-1 (LSD1). J Biol Chem. 2014;289(43):29937- 29947.
44. Lee G, Zheng Y, Cho S, et al. Post-transcrip- tional regulation of de novo post-transcrip- tional regulation of de novo lipogenesis by mTORC1-S6K1-SRPK2 signaling. Cell. 2017;171(7):1545-1549.
45. Roux PP, Shahbazian D, Vu H, et al. RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates Cap-dependent transla- tion. J Biol Chem. 2007;282(19):14056- 14064.
46. Maiques-Diaz A, Spencer GJ, Lynch JT, et al. Enhancer activation by pharmacologic dis- placement of LSD1 from GFI1 induces dif- ferentiation in acute myeloid leukemia. Cell Rep. 2018;22(13):3641-3659.
haematologica | 2020; 105(8)
2117